Profits rise 11% At Gist-Brocades In 1994

26 March 1995

Net profits before extraordinary income and expenses grew 11% to 141.2 million guilders ($89.5 million) in 1994 at Dutch company Gist-Brocades. The increase was in line with expectations. In 1993, profit had risen 23%. Operating profits grew 6% to 175 million guilders, representing 9.9% of turnover. The profit margin on industrial pharmaceutical products was up on 1993.

Net turnover rose 3.9% to 1.8 billion guilders. Growth was said to have been principally driven by the constant demand for industrial pharmaceutical products, which the company said had provided the most important contribution to the increase. Turnover was adversely affected by fluctuations in exchange rates to the tune of 15 million guilders.

Gist-Brocades has started construction of a production plant for 40-60 tonnes of clavulanic acid in Strangnas in Sweden.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight